Clinical Trial: BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07715136) titled 'BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy' on July 06.

Brief Summary: This single-arm, open-label, phase I trial evaluates the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with refractory Idiopathic inflammatory myopathy (IIM).

Study Start Date: March 20, 2025

Study Type: INTERVENTIONAL

Condition: Inflammatory Myopathy

Intervention: BIOLOGICAL: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T

Anti-BCMA, Anti-CD19 Compound CAR-T cells

Recruitment Status: RECRUITING

Sponsor: iCell Gene Therapeutics

Published by HT Digital Content Services with per...